Role of neutralizing antibodies in protective immunity against HIV
- PMID: 17038830
- DOI: 10.4161/hv.1.2.1764
Role of neutralizing antibodies in protective immunity against HIV
Abstract
HIV continues to be a major health problem world wide, however the situation is particularly serious in Asian and Sub-Saharan countries. Therefore, development of an effective HIV vaccine could help to reduce the severity of the disease and prevent infection. Over the last two decades significant efforts have been made towards inducing potent humoral and cellular immune responses by vaccination, however antibodies and CTL responses alone are likely not sufficient for inducing sterilizing immunity or long-term control of viral replication. Therefore, it is generally believed that both humoral and cellular responses will be needed for an effective HIV vaccine. In support of humoral immunity, monoclonal antibodies that recognize critical neutralizing epitopes have shown to be effective at passive transfer experiments in conferring protection against challenge infection. However, antibodies to similar epitope specificities are difficult to induce by vaccination. Therefore, optimization of Env structure is needed for exposing appropriate neutralizing epitopes and masking non-neutralizing epitopes. Since the crystal structure of the core of Env glycoprotein has been solved, efforts are in progress to design novel Env immunogens that may induce effective neutralizing responses. Furthermore, there are HIV-1 strains that are resistant to neutralization by monoclonal antibodies, yet neutralized by pooled sera from HIV-1 patients. Therefore, efforts should be made to identify these novel epitopes and to design strategies to incorporate them in potential vaccines. To facilitate comparative evaluation of vaccine immunogens for their ability to induce cross clade neutralizing antibodies, efforts should be made to use standardized neutralization assays and standard virus panels. Once potent HIV Env structure have been identified, their effectiveness may be enhanced through the use of adjuvants, delivery systems and prime and boost strategies to improve the quality and magnitude of neutralizing responses.
Similar articles
-
Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15. J Virol. 2016. PMID: 26763999 Free PMC article.
-
Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.J Virol. 2017 Sep 12;91(19):e00401-17. doi: 10.1128/JVI.00401-17. Print 2017 Oct 1. J Virol. 2017. PMID: 28490585 Free PMC article.
-
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.J Virol. 2017 Sep 12;91(19):e00991-17. doi: 10.1128/JVI.00991-17. Print 2017 Oct 1. J Virol. 2017. PMID: 28747500 Free PMC article.
-
Passive immunization as tool to identify protective HIV-1 Env epitopes.Curr HIV Res. 2007 Nov;5(6):642-55. doi: 10.2174/157016207782418506. Curr HIV Res. 2007. PMID: 18045119 Review.
-
Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S33-52. doi: 10.1586/14760584.3.4.s33. Expert Rev Vaccines. 2004. PMID: 15285704 Review.
Cited by
-
Immunologic, metabolic and genetic factors in hepatitis C virus infection.World J Gastroenterol. 2014 Apr 7;20(13):3443-56. doi: 10.3748/wjg.v20.i13.3443. World J Gastroenterol. 2014. PMID: 24707127 Free PMC article. Review.
-
Neutralizing antibodies and pathogenesis of hepatitis C virus infection.Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016. Viruses. 2012. PMID: 23202451 Free PMC article. Review.
-
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.J Virol. 2007 Oct;81(19):10209-19. doi: 10.1128/JVI.00872-07. Epub 2007 Jul 18. J Virol. 2007. PMID: 17634242 Free PMC article. Review. No abstract available.
-
HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies.J Virol. 2011 Jan;85(2):1077-85. doi: 10.1128/JVI.01619-10. Epub 2010 Nov 17. J Virol. 2011. PMID: 21084491 Free PMC article.
-
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.J Virol. 2008 Dec;82(24):12094-103. doi: 10.1128/JVI.01730-08. Epub 2008 Oct 8. J Virol. 2008. PMID: 18842728 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical